Hacker News Reader

Not familiar with tumor immunology but I’d imagine it could be challenging to get CAR-Ts to infiltrate the tumor on demand.

View on HN

Not a medical guy but ipilimumab and friends may help do that. They blockade ctla-4 which downregulates cd4 activity. A combination may result in enhanced results.

Reply on news.ycombinator.com